This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.

NCT07739784 | Recruiting

• 1 other identifier: 2026-10903
• Study Type: observational
• Target: 352
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn whether personality traits are related to eye side effects from glaucoma medications in adults who currently use or previously used these medications. The main questions this study aims to answer are: Are certain personality traits associated with the occurrence or severity of eye side effects from glaucoma medications? Do personality traits differ between people who experience these side effects and those who do not? Participants will complete a questionnaire that measures five personality traits: openness, conscientiousness, extraversion, agreeableness, and neuroticism. They will also provide basic demographic information. The researchers will review participants' medical records to collect information about their glaucoma medications and any related eye side effects, including the type and frequency of side effects and whether treatment was changed because of them. Participation involves one session lasting approximately 30 minutes. Questionnaires may be completed securely online or in person at the clinic. The study will include approximately 352 adults. No treatment will be assigned or changed as part of this study.

Conditions

Glaucoma

Keywords

adverse events; Personality traits; glaucoma

Outcome Measures

Primary Outcomes (1)

• Difference in Five-Factor Model neuroticism scores between participants with and without significant ocular adverse reactions

  Neuroticism will be measured using the neuroticism domain of the Five-Factor Model personality questionnaire. Mean neuroticism scores will be compared between: Cases: participants who experienced at least one ocular adverse effect from a glaucoma medication that resulted in discontinuation of the medication. Controls: participants who did not experience a significant ocular adverse effect resulting in medication discontinuation. Higher neuroticism scores indicate a higher level of the neuroticism personality trait.

  Assessed once during the single study session, lasting approximately 30 minutes.

Study Arms (2)

Case

Participants with at least one documented ocular adverse effect from a glaucoma medication that resulted in discontinuation of the medication.

Other: No Interventions

Control

Participants without a documented significant ocular adverse effect resulting in medication discontinuation.

Other: No Interventions

Interventions

No Interventions OTHER

There is no intervention

Case; Control

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Approximately 352 adults with glaucoma who are currently receiving or have previously received treatment with one or more glaucoma medications will be recruited from the McGill Academic Eye Centre and the Lachine Hospital Ophthalmology Clinic. Participants will be classified into two groups: Cases: Participants with at least one documented ocular adverse effect from a glaucoma medication that resulted in discontinuation of the medication. Controls: Participants without a documented significant ocular adverse effect resulting in medication discontinuation. Approximately 176 participants will be included in each group

You may qualify if:

• Age 18 years or older.
• Diagnosis of glaucoma.
• Current or previous treatment with one or more glaucoma medications.
• Able to provide informed consent.
• Able to complete the study questionnaires in English or French.

You may not qualify if:

• Uncontrolled anxiety or depression that was present before glaucoma medication treatment began.
• Unable to provide informed consent.
• Unable to complete the study questionnaires in English or French.

Sponsors & Collaborators

• McGill University Health Centre/Research Institute of the McGill University Health Centre: lead

Study Sites (1)

McGill University Health Center

Montreal, Quebec, Canada

RECRUITING

Related Publications (5)

• Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014 May 12;8:903-13. doi: 10.2147/OPTH.S44708. eCollection 2014.

  PMID: 24872675 RESULT

• Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, Hunter R, Bunce C, Nathwani N, Barton K; LiGHT Trial Study Group. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension. Ophthalmology. 2023 Feb;130(2):139-151. doi: 10.1016/j.ophtha.2022.09.009. Epub 2022 Sep 17.

  PMID: 36122660 RESULT

• Davis C, Ralevski E, Kennedy SH, Neitzert C. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. J Clin Psychopharmacol. 1995 Oct;15(5):347-52. doi: 10.1097/00004714-199510000-00007.

  PMID: 8830066 RESULT

• Dahl AA, Smedsland SK, Vandraas KF, Bohn SK, Falk RS, Kiserud CE, Reinertsen KV. High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors. Breast Cancer Res Treat. 2023 Nov;202(1):97-104. doi: 10.1007/s10549-023-07055-2. Epub 2023 Aug 1.

  PMID: 37528264 RESULT

• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008 Nov;86(7):716-26. doi: 10.1111/j.1755-3768.2008.01250.x. Epub 2008 Jun 3.

  PMID: 18537937 RESULT

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases

Study Officials

• Hady Saheb, MD MPH

  MUHC RI

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ana Hernandez, MD

CONTACT

15149341934; ana.ramirezhernandez@mail.mcgill.ca

Hady Saheb, MD MPH

CONTACT

514-934-1934; hady.saheb@mcgill.ca

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Ophthalmology

Study Record Dates

• First Submitted: July 28, 2026
• First Posted: July 31, 2026
• Study Start: February 25, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): August 1, 2027
• Last Updated: July 31, 2026

Record last verified: 2026-07

Locations

CA (1)